What kind of medicine is Acemini? How does it work?

Aximini, as an innovative drug, its active substance is a tyrosine kinase inhibitor (TKI). This substance blocks the activity of tyrosine kinase, a key enzyme. During the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), the patient's body abnormally produces a large number of white blood cells, and the proliferation of these white blood cells is closely related to the activity of BCR-ABL1 tyrosine kinase. Aceminib helps patients control their disease by specifically acting on the BCR-ABL1 tyrosine kinase produced by these cells, effectively preventing their division and growth.

The drug has a wide range of indications and is specifically suitable for adult patients with Ph+ CML in the chronic phase who have previously received two or more tyrosine kinase inhibitors but have not achieved satisfactory results In addition, aceminib also showed significant therapeutic effects on adult patients with chronic phase Ph+ CML with T315I mutation, as well as newly diagnosed patients with chronic phase Ph+ CML.

Clinical studies have shown that in a population of patients who have been treated with at least two prior tyrosine kinase inhibitors, aceminib showed superior efficacy than another tyrosine kinase inhibitor in reducing the number of cells carrying theBCR-ABL1 gene. This not only provides patients with more treatment options, but also further improves the effectiveness of treatment and the quality of life of patients.

In terms of safety, aceminib's side effects are similar to other similar drugs and are generally considered manageable. This means that patients can relatively safely focus on the improvement of their condition during treatment without having to worry too much about the additional risks that may be brought about by the drug.

In short, as an innovative tyrosine kinase inhibitor, aceminib brings new treatment hope toPh+ CML patients with its unique mechanism and significant clinical effect. Its wide range of indications and controllable safety make Asiminib a trustworthy treatment option for many patients.

References:

https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix